These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 14635075)

  • 21. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
    Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
    J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
    Oyama A; Ota K; Asano S; Takaku F; Yoshida Y; Uzuka Y; Omine M; Furusawa S; Takatani O; Sawada U
    Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2533-48. PubMed ID: 1702132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study of optimal CHOP dose ranges for elderly patients with non-Hodgkin's lymphoma].
    Mori M; Murai Y; Suzuki K; Nonaka Y; Sato H; Tomiyama J; Takagi T; Muto Y; Kashimura M
    Rinsho Ketsueki; 1999 Mar; 40(3):199-204. PubMed ID: 10222626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
    Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
    J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
    Lyman GH; Morrison VA; Dale DC; Crawford J; Delgado DJ; Fridman M; ;
    Leuk Lymphoma; 2003 Dec; 44(12):2069-76. PubMed ID: 14959849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
    Balducci L; Mo M; Abella E; Saven A
    Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity.
    Brusamolino E; Bertini M; Guidi S; Vitolo U; Inverardi D; Merante S; Colombo A; Resegotti L; Bernasconi C; Ferrini PR
    Haematologica; 1988; 73(3):217-22. PubMed ID: 3139519
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
    J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
    Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M
    Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
    Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
    J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
    J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
    Oyama A; Ota K; Asano S; Takaku F; Miyazaki T; Uzuka Y; Omine M; Furusawa S; Hirashima K; Sanpi K
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1619-34. PubMed ID: 1700040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
    Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
    [No Abstract]   [Full Text] [Related]  

  • 37. [High-dose biweekly CHOP chemotherapy with granulocyte colony-stimulating factor support for patients with aggressive non-Hodgkin lymphoma].
    Taguchi H; Shishido T; Niitsu N; Hiraoka A; Kageyama T; Kanamaru A; Ogawa M
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):523-9. PubMed ID: 9530358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
    Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
    J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.